Table 1.
Patient characteristics
Subject ID | Sex | Age, y | Handednessa | Tumor lateralization | Tumor location | Tumor size, cm3 | Tumor histologyb |
---|---|---|---|---|---|---|---|
PAT01 | F | 67 | 1.00 | Left | Frontal | 1.69 | Meningioma I |
PAT02 | F | 49 | 1.00 | Right | Frontal | 0.75 | Meningioma I |
PAT03 | F | 60 | 1.00 | Right | Parietal | 78.44 | Meningioma I |
PAT05 | F | 40 | 1.00 | Left | Frontal | 12.95 | Oligo-astrocytoma II |
PAT06 | F | 67 | 1.00 | Bilateral | Frontal | 12.81 | Meningioma I |
PAT07 | M | 55 | -0.16 | Left | Temporal | 33.94 | Ependymoma II |
PAT08 | M | 51 | 1.00 | Left | Frontal | 16.81 | Meningioma I |
PAT10 | F | 77 | 1.00 | Left | Frontal | 0.59 | Meningioma I |
PAT11 | F | 74 | 1.00 | Left | Frontal | 20.73 | Meningioma II |
PAT13 | F | 40 | -0.68 | Bilateral | Skull base | 2.09 | Meningioma I |
PAT14 | F | 74 | 1.00 | Left | Parietal | 3.45 | Meningioma I |
PAT15 | F | 57 | 1.00 | Right | Frontal | 2.13 | Meningioma I |
PAT16 | M | 39 | 1.00 | Right | Fronto-temporal | 50.24 | Anaplastic astrocytoma II–III |
PAT17 | F | 49 | 1.00 | Right | Frontal | 0.58 | Meningioma I |
PAT19 | F | 44 | 1.00 | Right | Frontal skull base | 2.64 | Meningioma I |
PAT20 | F | 70 | 0.60 | Right | Parietal | 15.24 | Anaplastic astrocytoma III |
PAT22 | M | 53 | 1.00 | Right | Parietal | 15.16 | Oligodendroglioma II |
PAT23 | M | 74 | 1.00 | Bilateral | Frontal | 89.56 | Meningioma I |
PAT24 | M | 62 | 1.00 | Left | Frontal | 5.91 | Meningioma I |
PAT25 | F | 46 | 1.00 | Right | Temporal | 18.56 | Glioma II |
PAT26 | M | 61 | 1.00 | Right | Temporal | 59.21 | Anaplastic astrocytoma III |
PAT27 | M | 38 | 1.00 | Left | Frontal | 13.24 | Astrocytoma II |
PAT28 | M | 44 | 1.00 | Left | Frontal | 11.49 | Oligodendroglioma II |
PAT29 | M | 45 | 0.90 | Left | Frontal | 36.20 | Oligodendroglioma III |
PAT31 | F | 31 | 0.90 | Left | Frontal | 4.24 | Oligodendroglioma II |
–1, left-handed; 0, ambidextrous; +1, right-handed.
(Oligo-)astrocytoma, ependymoma, and oligodendroglioma are subtypes of glioma tumors. See also Table 1-1.